On Thursday, Fiat Chrysler Automobiles NV (NYSE:FCAU)’s shares declined -1.09% to $14.56.
Fiat Chrysler Automobiles NV (FCAU) has beta value of 1.97. The company has the market capitalization of $18.91 billion. Return on assets ratio of the company was 1.00% while its return on equity ratio was 7.30%. ATR value of company was 0.51 while stock volatility for week was 2.90% while for month was 2.79%. Debt to equity ratio of the company was -2.26 and its current ratio was 1.30.
Fiat Chrysler Automobiles N.V., an automotive group, designs, engineers, manufactures, distributes, and sells vehicles and components. It offers passenger cars, light trucks, and light commercial vehicles under the Abarth, Alfa Romeo, Chrysler, Dodge, Fiat, Fiat Professional, Jeep, Lancia, and Ram brand names, in addition to after-sales services and parts under the Mopar brand name.
Barrick Gold Corporation (USA) (NYSE:ABX)’s shares gained 1.69% to $7.82.
Barrick Gold Corporation (USA) (ABX) offered 12.40% EPS for prior five years. The company has -24.40% return on equity value while its ROI ratio was -9.30%. The company has $8.91 billion market capitalizations and the institutional ownership was 72.10%. Its price to book ratio was 0.90. Volatility of the stock was 6.16% for the week while for the month booked as 5.27%.
Barrick Gold Corporation (Barrick) is a gold mining company. The Company is engaged in the production and sale of gold and copper, in addition to related activities, such as exploration and mine development. The Company operates in segments: eight individual gold mines, Acacia and Pascua-Lama project. The remaining operating segments have been grouped into two other categories: its remaining gold mines and its two copper mines.
At the end of Thursday’s trade, Endo International (NASDAQ:ENDP)‘s shares dipped -0.84% to $60.38.
Endo International (ENDP) is currently valued at $13.79 billion. The company has 226.40 million shares outstanding and 99.80% shares of the company were owned by institutional investors. The company has 4.54 value in price to sale ratio while price to book ratio was recorded as 1.82. The company exchanged hands with 6.41 million shares as compared to its average daily volume of 5.77 million shares. It beta stands at 1.43.
Endo Pharmaceuticals Inc., a partner of Endo International plc (ENDP) (ENL.TO), and BioDelivery Sciences International, Inc. (BDSI), declared recently that the U.S. Food and Drug Administration (FDA) has approved BELBUCA™ (buprenorphine) buccal film for use in patients with chronic pain severe enough to require daily, around-the-clock, long-term opioid treatment and for which alternative treatment options are inadequate. BELBUCA™, which is the first and only buprenorphine developed with a dissolving film that is absorbed through the inner lining of the cheek for chronic pain administration, is predictable to be commercially available in the U.S. during the first quarter of 2016 in seven dosage strengths, allowing for flexible dosing ranging from 75 micrograms to 900 micrograms every 12 hours. This enables physicians to individualize titration and treatment based on the optimally effective and tolerable dose for each patient.
“The availability of new, convenient and flexible treatment options is important for patients whose lives are burdened by chronic pain, a debilitating condition that affects more Americans than diabetes, heart disease and cancer combined,” said Richard L. Rauck, M.D., Director of Carolinas Pain Institute, Winston Salem, NC. “BELBUCA™ provides a unique approach for chronic pain administration, combining the proven efficacy and established safety of buprenorphine with a novel buccal film delivery system that adds convenience and flexibility. For both opioid-naive and opioid-practiced patients who require around-the-clock treatment and for whom alternative treatment options are inadequate, BELBUCA™ offers appropriate, compriseent pain relief and a low incidence of typical opioid-like side effects.”
Endo International plc, a specialty healthcare company, focuses on branded and generic pharmaceuticals and devices worldwide. It operates through four segments: U.S. Branded Pharmaceuticals, U.S. Generic Pharmaceuticals, Devices, and International Pharmaceuticals. The U.S. Branded Pharmaceuticals segment provides various branded prescription products, counting Lidoderm, Opana ER, Voltaren Gel, Percocet, Frova, Fortesta Gel, Supprelin LA, Valstar, Vantas, Sumavel DosePro, Aveed, and Natesto to treat and manage pain and conditions in urology, endocrinology, and oncology.